Why did Merck issue an unusual press release? It knows investors are hyperfocused on I-O data

Investors falsely suspected Merck was sitting on negative Keytruda data last week. (Merck)

Investor “conspiracy theories” are real in immuno-oncology, something Merck & Co. knows all too well. So well, in fact, that the company recently changed up its communications game to address investor fears directly.

It all started last on Merck’s first-quarter conference call, when the company confirmed that data from the Keynote-407 trial—which is examining Keytruda alongside two different chemo regimens as a treatment for first-line, metastatic squamous non-small cell lung cancer—would be released at June’s American Society of Clinical Oncology (ASCO) annual meeting.

The thing was, Merck hadn’t yet released any top-line data from that trial, a factor that “led to fears that perhaps Merck was sitting on bad data,” Bernstein analyst Tim Anderson wrote in a note to clients.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

But that wasn’t the case, and to set the story straight, Merck issued a press release with an earlier-than-normal data disclosure: The cocktail had nailed its response-rate marks, hitting a secondary endpoint for the trial. And based on that performance, it had filed the regimen for FDA approval.

As Anderson pointed out, Merck “would not normally put out a press release like this based on an ORR analysis as part of a secondary endpoint, even if it had filed for approval with FDA, as it has in this instance.” Instead, it would generally wait until the filing had been accepted or until the regimen had hit the study’s primary endpoint to come out publicly with the news.

RELATED: Warning to I-O drugmakers: If investors were hyperfocused on data this year, just wait till 2018

Evercore ISI’s Umer Raffat applauded the New Jersey drugmaker’s decision, writing in his own note to clients that the tidbits included in the press release “check the box and put any KN-407 controversy to rest.”

“This is good news … and should calm down conspiracy theories” on the trial, he wrote.

But beyond hinting at Merck’s hand, the move illustrated the pressure on companies—immuno-oncology drugmakers in particular—that’s coming from shareholders, who are monitoring the I-O landscape like hawks and have been known to let fears run wild and run down a stock based on a false premise.  

RELATED: With 'Dear Scientist' campaign from BG BrandLab, Pfizer keeps researchers in the spotlight

The desire to play directly to shareholders extends beyond I-O, though. A wave of recent pharma corporate image campaigns have served dual purposes: portraying a culture of innovation to consumers increasingly focused on drug prices, and allaying fears from shareholders worried that government and payer drug-pricing action could hurt shares.

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.